Notizie e Video - NOVAVAX INC.

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024 PR Newswire GAITHERSBURG, Md., May 7, 2024 GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024 . Details of the...

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 PR Newswire GAITHERSBURG, Md., April 1, 2024 GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and...

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire GAITHERSBURG, Md., Feb. 29, 2024 GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44 th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston...

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Feb. 28, 2024 Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023 Announced settlement with Gavi related to...

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement PR Newswire GAITHERSBURG, Md. and GENEVA, Feb. 22, 2024 GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a...

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024 PR Newswire GAITHERSBURG, Md., Feb. 20, 2024 GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time...

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire GAITHERSBURG, Md., Jan. 3, 2024 GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42 th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST)...

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan PR Newswire GAITHERSBURG, Md., Dec. 18, 2023 Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid ™ XBB.1.5...

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada PR Newswire GAITHERSBURG, Md., Dec. 5, 2023 Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5...

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization PR Newswire GAITHERSBURG, Md., Nov. 28, 2023 GAITHERSBURG, Md. , Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active...

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities PR Newswire GAITHERSBURG, Md., Nov. 17, 2023 New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans John Trizzino appointed to new Chief Operating Officer role Mark Casey to join as Chief Legal Officer and Corporate Secretary GAITHERSBURG, Md. , Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc....

Novavax to Participate in Jefferies London Healthcare Conference PR Newswire GAITHERSBURG, Md., Nov. 10, 2023 GAITHERSBURG, Md. , Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference. Conference Details: Fireside Chat Date: Wednesday, November 15, 2023 Time: 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) Location: London...

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Nov. 9, 2023 Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option Secured broad access to Novavax's COVID-19 vaccine in the U.S. R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch Anticipate...

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023 PR Newswire GAITHERSBURG, Md., Nov. 2, 2023 GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023...

Novavax's Updated COVID-19 Vaccine Now Approved in the EU PR Newswire GAITHERSBURG, Md., Oct. 31, 2023 Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU member states to bring its updated COVID-19 vaccine to those that have requested doses through the advance purchase agreement GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq:...

Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU PR Newswire GAITHERSBURG, Md., Oct. 31, 2023 Pending a European Commission decision, Novavax's vaccine will be the only updated protein-based non-mRNA COVID-19 vaccine available in Europe for individuals aged 12 and older GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that the...

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom PR Newswire GAITHERSBURG, Md., Oct. 18, 2023 Full authorization of prototype enables rapid authorization of updated Novavax COVID-19 vaccines in future GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Medicines and Healthcare products Regulatory...

Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore PR Newswire GAITHERSBURG, Md., Oct. 18, 2023 GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ™ adjuvant, today announced that Singapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in...

Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S. PR Newswire GAITHERSBURG, Md., Oct. 13, 2023 Novavax's updated COVID-19 vaccine is now available at a wide range of retailers, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid, Stop & Shop and Topco Novavax's vaccine is the only protein-based non-mRNA COVID-19 vaccine option in the U.S. Novavax's vaccine finder is available at us.novavaxcovidvaccine.com GAITHERSBURG, Md. , Oct. 13, 2023 /PRNewswire/ --...

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023 PR Newswire GAITHERSBURG, Md., Oct. 11, 2023 GAITHERSBURG, Md. , Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15 , and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October...